In response to the requirements of
section 122 of the Food and Drug Modernization Act of 1997, the
Food and Drug Administration is proposing to amend the drug and
biologics regulations by adding provisions that would clarify the
evaluation and approval of in vivo radiopharmaceuticals used in the
diagnostic radiopharmaceuticals under the Federal Food, Drug, and
Cosmetic Act and the Public Health Service Act.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.